Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4433251 | 0.86 | EPHX1 (0.53) | MMP1MMP2EPHX1LMNAALDH1A1 | |
| SCHEMBL11698967 | 0.84 | EPHX1 (0.62) | EPHX1LMNAALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL14008166 | 0.82 | EPHX1 (0.66) | EPHX1ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL22472041 | 0.82 | EPHX1 (0.66) | EPHX1ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL14008172 | 0.82 | EPHX1 (0.66) | EPHX1ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL6592214 | 0.79 | — | — | |
| SCHEMBL1534214 | 0.78 | KDM4C (0.41) | MMP1MMP2MMP3MMP9EPHX1 | |
| SCHEMBL4280908 | 0.77 | LMNA (0.43) | EPHX1LMNAALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL13660337 | 0.77 | MEN1 (0.58) | EPHX1LMNAALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL13660344 | 0.77 | MEN1 (0.58) | EPHX1LMNAALDH1A1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586612-B2 | Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-11-19 | — | — | US | disclosed |
| US-20130035479-A1 | FUNCTIONALIZED BETA 1,6 GLUCOSAMINE DISACCHARIDES AND PROCESS FOR THEIR PREPARATION | OM PHARMA (CH) | 2013-02-07 | — | — | US | disclosed |
| CN-101080388-B | Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them | SANOFI AVENTIS DEUTSCHLAND | 2010-12-22 | — | — | CN | disclosed |
| US-20100168054-A1 | Functionalized Beta 1,6 Glucosamine Disaccharides and Process for Their Preparation | OM PHARMA (CH) | 2010-07-01 | — | — | US | disclosed |
| EP-2106403-A2 | FUNCTIONALIZED BETA 1,6 GLUCOSAMINE DISACCHARIDES AND PROCESS FOR THEIR PREPARATION | OM Pharma (CH) | 2009-10-07 | — | — | EP | disclosed |
| EP-1828131-B1 | PIPERIDINESULFONYLUREAS AND -THIOUREAS, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-06-04 | — | — | EP | disclosed |
| WO-2008059035-A2 | FUNCTIONALIZED BETA 1,6 GLUCOSAMINE DISACCHARIDES AND PROCESS FOR THEIR PREPARATION | OM PHARMA (CH) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008059307-A2 | FUNCTIONALIZED BETA 1,6 GLUCOSAMINE DISACCHARIDES AND PROCESS FOR THEIR PREPARATION | OM PHARMA (CH) | 2008-05-22 | — | — | WO | disclosed |
| US-20080033016-A1 | Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-07 | — | — | US | disclosed |
| CN-101080388-A | Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-11-28 | — | — | CN | disclosed |
| EP-1828131-A1 | PIPERIDINESULFONYLUREAS AND -THIOUREAS, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Sanofi-Aventis Deutschland GmbH (DE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006063722-A1 | PIPERIDINESULFONYLUREAS AND -THIOUREAS, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-06-22 | — | — | WO | disclosed |
| EP-0842927-B1 | 3-Amido-chromanylsulfonyl(thio)ureas, process for their preparation, their use and medicaments containing them | AVENTIS PHARMA GMBH (DE) | 2004-02-25 | — | — | EP | disclosed |
| EP-0779288-B1 | Substituted chromanylsulfonyl(thio)ureas, process for their preparation, their use in pharmaceutical compositions and preparations containing them | HOECHST AG (DE) | 2000-03-29 | — | — | EP | disclosed |
| US-5849755-A | 3-amidochromanylsulfonyl(thio)ureas, processes for their preparation, their use, and pharmaceutical preparations comprising them | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-12-15 | — | — | US | disclosed |
| US-5811448-A | PHARMACEUTICALS USEFUL FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-09-22 | — | — | US | disclosed |
| EP-0842927-A1 | 3-Amido-chromanylsulfonyl(thio)ureas, process for their preparation, their use and medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-05-20 | — | — | EP | disclosed |
| EP-0779288-A1 | Substituted chromanylsulfonyl(thio)ureas, process for their preparation, their use in pharmaceutical compositions and preparations containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035479-A1 | FUNCTIONALIZED BETA 1,6 GLUCOSAMINE DISACCHARIDES AND PROCESS FOR THEIR PREPARATION | FUT6, FUT5, B3GNT2 | MMP1 467/4885MMP2 1106/4885MMP3 2017/4885 |
| US-20080033016-A1 | Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them | ATP2A1, ATP2A3, ATP2A2 | MMP1 3720/4885MMP2 4713/4885MMP3 4761/4885 |
| US-20100168054-A1 | Functionalized Beta 1,6 Glucosamine Disaccharides and Process for Their Preparation | FUT6, FUT5, B3GNT2 | MMP1 467/4885MMP2 1106/4885MMP3 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.